Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by M. Jianfar
Acalabrutinib With Obinutuzumab in Treatment-Naive and Relapsed/Refractory Chronic Lymphocytic Leukemia: 3-Year Follow-Up
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Related publications
Phase 2 Study of Acalabrutinib in Ibrutinib-Intolerant Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Phase 1b Study of Venetoclax-Obinutuzumab in Previously Untreated and Relapsed/Refractory Chronic Lymphocytic Leukemia
Blood
Biochemistry
Immunology
Cell Biology
Hematology
Analysis of Treatment Options for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Acalabrutinib vs Rituximab Plus Idelalisib (IdR) or Bendamustine (BR) by Investigator Choice in Relapsed/Refractory (RR) Chronic Lymphocytic Leukemia: Phase 3 ASCEND Study
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Psy81 - Direct Costs Associated With the Treatment of Chronic Lymphocytic Leukemia (Cll) Relapsed or Refractory in Argentina
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Cost-Utility of Idelalisib in Combination With Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Real World Outcomes of Obinutuzumab Monotherapy in Patients With Chronic Lymphocytic Leukemia
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Outcomes With Bruton Tyrosine Kinase Inhibition in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma After Progression on Venetoclax
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Profile of Obinutuzumab for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia
OncoTargets and Therapy
Oncology
Pharmacology
